Skye Bioscience AI Stock Analysis
Want to see SKYE full AI Analyst Report?
Skye Bioscience (SKYE) AI Stock Analysis
Skye Bioscience
(NASDAQ:SKYE)
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and sustained cash burn alongside a shrinking equity cushion). Technicals also point to a bearish trend with the price below key moving averages and negative MACD. Corporate events provide some offset via merger/financing developments, but Nasdaq compliance and delisting risk temper that benefit; valuation signals are limited due to negative earnings and no dividend yield data.
Skye Bioscience (SKYE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.48M
- Dividend Yield
- ―
- Average Volume (3M)
- 85.95K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 3.75
- Revenue Growth
- ―
- EPS Growth
- 26.40%
- Country
- US
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Skye Bioscience Business Overview & Revenue Model
Company Description
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripher...
Skye Bioscience Earnings Call Summary
The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.
Q3-2025 Updates
Positive Updates
Negative Updates
Company Guidance
In the Skye Bioscience, Inc. third-quarter 2025 earnings call, the company provided detailed guidance on its financial and clinical development milestones. Key financial highlights included ending the quarter with $35.3 million in cash and equivalents, with expectations to fund operations into 2027. R&D expenses increased to $9.4 million from $4.9 million in the previous year due to ongoing clinical trials, including those for Nolasimab and Nimazumab. Notably, the company reported a net loss of $12.8 million, attributed partly to non-cash share-based compensation expenses. Clinical updates focused on the promising results from the Phase 2a CBEYOND study, showing a 3% additional weight loss with Nimazumab plus semaglutide compared to semaglutide alone, with a significant p-value of 0.0372. The study also demonstrated improvements in lean to fat mass ratio and reduced waist circumference, with retention strong in the extension study. The company is advancing Nimazumab's dose concentration strategy and plans to evaluate higher doses in future studies, keeping scalability and patient convenience in focus.
Skye Bioscience Financial Statement Overview
Summary
Financials reflect a pre-revenue biotech with $0 revenue, persistent and sizable net losses, and continued negative operating/free cash flow (TTM operating cash flow about -$30.6M). While reported debt is minimal, the equity base has sharply deteriorated over time, reducing financial flexibility and increasing financing risk.
Income Statement
12Very NegativeBalance Sheet
42NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -204.21K | -723.35K | 0 | 0 | 0 | 0 |
| EBITDA | -42.16M | -55.20M | -25.29M | -36.62M | -18.70M | -7.72M |
| Net Income | -37.67M | -55.92M | -26.57M | -37.64M | -19.48M | -8.52M |
Balance Sheet | ||||||
| Total Assets | 5.07M | 28.31M | 72.76M | 11.94M | 9.11M | 9.86M |
| Cash, Cash Equivalents and Short-Term Investments | 4.82M | 25.74M | 68.42M | 1.26M | 1.24M | 8.98M |
| Total Debt | 9,452 | 273.65K | 455.59K | 4.62M | 1.98M | 2.14M |
| Total Liabilities | 3.71M | 8.29M | 4.61M | 14.07M | 12.12M | 3.99M |
| Stockholders Equity | 1.36M | 20.02M | 68.15M | -2.13M | -3.01M | 5.86M |
Cash Flow | ||||||
| Free Cash Flow | -30.58M | -43.07M | -26.84M | -13.96M | -12.77M | -6.57M |
| Operating Cash Flow | -30.58M | -43.06M | -25.24M | -13.95M | -12.74M | -6.47M |
| Investing Cash Flow | 17.23M | -19.50M | -245.62K | 6.60M | 5.21M | -90.87K |
| Financing Cash Flow | -277.84K | 29.57K | 83.56M | 16.44M | -208.79K | 13.08M |
Skye Bioscience Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SKYE, the sentiment is Negative. The current price of 0.79 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.47, and below the 200-day MA of 4.38, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 31.95 is Neutral, neither overbought nor oversold. The STOCH value of 56.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SKYE.
Skye Bioscience Risk Analysis
Skye Bioscience disclosed 82 risk factors in its most recent earnings report. Skye Bioscience reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksSkye Bioscience Peers Comparison
Overall Rating
ATNM54Neutral
INMB49Neutral
OTLK46Neutral
SKYE40Underperform
LTRN40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 54Neutral | $33.64M | 3.24 | 65.18% | ― | 38788.89% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $27.68M | -1.44 | -81.71% | ― | -100.00% | 71.08% | |
| 46Neutral | $97.62M | -0.36 | 222.01% | ― | ― | ― | |
| 40Underperform | $3.48M | -0.10 | -503.95% | ― | ― | 26.40% | |
| 40Underperform | $4.51M | -0.24 | -674.37% | ― | ― | 32.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SKYE | Skye Bioscience, Inc. | 0.79 | -8.53 | -91.57% | |
| ATNM | Actinium Pharmaceuticals | 1.07 | -0.26 | -19.55% | |
| OTLK | Outlook Therapeutics | 0.40 | -1.48 | -78.67% | |
| INMB | Inmune Bio | 0.89 | -0.62 | -40.79% | |
| LTRN | Lantern Pharma, Inc. | 0.28 | -2.74 | -90.63% |
Skye Bioscience Corporate Events
Skye Bioscience Wins Jury Verdict in Employee Retaliation Lawsuit
PositiveA former Skye Bioscience employee filed a lawsuit alleging violations of Sarbanes-Oxley whistleblower protections and retaliation under California law over actions and events involving the company’s former management during employment from March 2018...
Skye Bioscience CFO Resigns, CEO Assumes Financial Role
NeutralOn September 8, 2026, Skye Bioscience terminated its Master Services Agreement with Lohman & Associates, coinciding with the resignation of Chief Financial Officer and principal financial and accounting officer John P. Sharp. The company stated that...
Skye Bioscience Establishes New Equity Financing Arrangements
PositiveOn August 21, 2026, Skye Bioscience entered into a Securities Purchase Agreement with Redmile Biopharma Investments III, L.P., establishing an equity line of credit of up to $22 million in common and non-voting common shares, with the final amount co...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
